Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000343351

Medchemexpress LLC Nemonoxacin malate | 951163-60-3 | 99.29% | 505.52 | 100 MG
SDP

Catalog No. 5000343351
Encompass_Preferred

Nemonoxacin malate is a nonfluorinated quinolone antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and atypical pathogens. It can inhibit drug-resistant *Streptococcus pneumoniae* and Methicillin-resistant *Staphylococcus aureus* and can be used for the research of community-acquired pneumonia.

  • Nonfluorinated quinolone antibiotic.
  • Broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens.
  • Inhibits drug-resistant *Streptococcus pneumoniae* and Methicillin-resistant *Staphylococcus aureus*.
  • Used for the research of community-acquired pneumonia.
  • Antibacterial activity against *Chlamydia pneumoniae* with MIC90s of 0.06 μg/mL.
  • Highly active against community-acquired MRSA (CA-MRSA) (MIC90: 0.5 and 0.06 μg/ml), and exerts limited activity against Ciprofloxacin-resistant MRSA (MIC90: 1 μg/ml), and Vancomycin-intermediate MRSA (MIC90: 2 μg/ml).

Catalog No. 50-003-43351 Supplier Medchemexpress LLC Supplier No. HY111023100MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Nemonoxacin malate is a nonfluorinated quinolone antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and atypical pathogens. It can inhibit drug-resistant *Streptococcus pneumoniae* and Methicillin-resistant *Staphylococcus aureus* and can be used for the research of community-acquired pneumonia.

  • Nonfluorinated quinolone antibiotic.
  • Broad-spectrum activity against Gram-positive, Gram-negative and atypical pathogens.
  • Inhibits drug-resistant *Streptococcus pneumoniae* and Methicillin-resistant *Staphylococcus aureus*.
  • Used for the research of community-acquired pneumonia.
  • Antibacterial activity against *Chlamydia pneumoniae* with MIC90s of 0.06 μg/mL.
  • Highly active against community-acquired MRSA (CA-MRSA) (MIC90: 0.5 and 0.06 μg/ml), and exerts limited activity against Ciprofloxacin-resistant MRSA (MIC90: 1 μg/ml), and Vancomycin-intermediate MRSA (MIC90: 2 μg/ml).

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.